Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice

Brain Research

Volumn 942, Issue 1-2, 2002, Pages 23-30

  Laufs, Ulrich ^a   Gertz, Karen ^b   Dirnagl, Ulrich ^b   Boöhm, Michael ^a   Nickenig, Georg ^a   Endres, Matthias ^b  

^a Medizinische Klinik und Poliklinik   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Cerebral ischemia; Endothelial nitric oxide synthase; Lipid metabolism; Stroke

Indexed keywords

ARGININE; ATORVASTATIN; CHOLESTEROL; CITRULLINE; COMPACTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; MEVINOLIN; NITRIC OXIDE SYNTHASE; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN PROTECTION; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME ASSAY; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

ANIMALS; BRAIN ISCHEMIA; CELLS, CULTURED; CEREBRAL INFARCTION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FLUOROBENZENES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFARCTION, MIDDLE CEREBRAL ARTERY; MICE; MICE, INBRED STRAINS; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE; PYRIMIDINES; REPERFUSION INJURY; RNA, MESSENGER; SULFONAMIDES; UP-REGULATION;

EID: 0037189048     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)02649-5     Document Type: Article

References (30)

1. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice
2. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
3. Pharmacology of competitive inhibitors of HMG-CoA reductase
4. Vascular effects of statins in stroke
5. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
6. DNA methyltransferase contributes to delayed ischemic brain injury
7. Neuroprotective effects of gelsolin during murine stroke
8. Regulation of the mevalonate pathway
9. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells
10. Hypertension in mice lacking the gene for endothelial nitric oxide synthase
11. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine
12. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within 2 weeks
13. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions
14. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase
15. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription
16. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice
17. Neuroprotection mediated by changes in the endothelial actin cytoskeleton
18. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
19. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias
20. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts
21. Endothelium and acute coronary syndromes
22. Molecular biology of atherosclerosis
23. Current perspectives on statins
24. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
25. Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat
26. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
27. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
28. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation
29. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
30. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment